Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol

被引：11
|
作者：
Yasui-Furukori, N
Kondo, T
Suzuki, A
Mihara, K
Tokinaga, N
Inoue, Y
Otani, K
Kaneko, S
机构：
[1] Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 036, Japan
[2] Welfide Corp, Pharmaceut Res Div, Fukuoka, Japan
[3] Yamagata Univ, Sch Med, Dept Neuropsychiat, Yamagata 99023, Japan
来源：
SCHIZOPHRENIA RESEARCH | 2001年 / 52卷 / 1-2期
关键词：
D O I：
10.1016/S0920-9964(00)00178-X
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：139 / 142
页数：4
相关论文
共 50 条
  • [1] Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
    Roh, HK
    Chung, JY
    Oh, DY
    Park, CS
    Svensson, JO
    Dahl, ML
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (03) : 265 - 271
  • [2] Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
    Suzuki, A
    Otani, K
    Mihara, K
    Yasui, N
    Kaneko, S
    Inoue, Y
    Hayashi, K
    PHARMACOGENETICS, 1997, 7 (05): : 415 - 418
  • [3] Effect of CYP2D6 genotype on duloxetine serum concentration
    Hole, Kristine
    Gangso, Sofie
    Jensstuen, Asa Tonette
    Ormoy, Hanne Holte
    Paulsen, Maren
    Molden, Espen
    Haslemo, Tore
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (01) : 186 - 192
  • [4] CYP2D6 genotype in psychiatric patients:: Impact on haloperidol metabolism.
    Schmider, J
    Sachse, C
    Walter, S
    Filler, D
    Kaiser, R
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 185 - 185
  • [5] CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese
    Kondo, T
    Suzuki, A
    Mihara, K
    Yasui, N
    Kaneko, S
    MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY, 1999, 1172 : 81 - 86
  • [6] Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
    Buster Mannheimer
    Johan Holm
    Larissa Koukel
    Leif Bertilsson
    Urban Ösby
    Erik Eliasson
    European Journal of Clinical Pharmacology, 2014, 70 : 695 - 699
  • [7] Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
    Mannheimer, Buster
    Holm, Johan
    Koukel, Larissa
    Bertilsson, Leif
    Osby, Urban
    Eliasson, Erik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (06) : 695 - 699
  • [8] Impact of CYP2D6 Genotype on Paroxetine Serum Concentration
    Hole, Kristine
    Haslemo, Tore
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 683 - 688
  • [9] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [10] CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
    Scordo, MG
    Spina, E
    Romeo, P
    Dahl, ML
    Bertilsson, L
    Johansson, I
    Sjöqvist, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) : 679 - 683
12345